Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast Cancer
Enrolling By Invitation
99 years and younger
All
Phase
1
1 Location
Brief description of study
See protocol section 2 See protocol section 2 See protocol section 2
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 852205
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
